BACKGROUND: Buprenorphine, a synthetic molecule derived from thebaine, has been commercialized in France since 1987 as a substitute treatment for pharmacodependence on opiates. Hepatotoxicity is poorly documented, since only few cases of hepatic injury have been reported. METHODS: We report seven cases of acute cytolytic hepatitis due to buprenorphine. All patients were former drug addicts by the parenteral route and had been receiving withdrawal therapy with buprenorphine for an average of 91 days at a daily dosage ranging from 2 to 12 mg. Liver tests, complete viral screening and an abdominal computerized tomography scan were performed in each patient. RESULTS: Five out of seven subjects presented with acute icteric hepatitis without abdominal pain or fever. Average alanine aminotransferase levels were 39 times the normal rate. There was no sign of liver failure. All patients had anti-hepatitis C virus-positive serology and two had positive hepatitis C virus-RNA. Although no specific treatment was administered, buprenorphine doses were reduced whenever possible. Cytolysis and jaundice resolved rapidly in all cases, although treatment was continued at the same doses in four cases and the dosage was reduced by 50% in three other cases. CONCLUSIONS: Although buprenorphine hepatitis is uncommon and has spontaneously good evolution, we suggest better monitoring of hepatic profiles in patients whose mitochondrial function is already impaired by viral infections or other toxic factors.
BACKGROUND:Buprenorphine, a synthetic molecule derived from thebaine, has been commercialized in France since 1987 as a substitute treatment for pharmacodependence on opiates. Hepatotoxicity is poorly documented, since only few cases of hepatic injury have been reported. METHODS: We report seven cases of acute cytolytic hepatitis due to buprenorphine. All patients were former drug addicts by the parenteral route and had been receiving withdrawal therapy with buprenorphine for an average of 91 days at a daily dosage ranging from 2 to 12 mg. Liver tests, complete viral screening and an abdominal computerized tomography scan were performed in each patient. RESULTS: Five out of seven subjects presented with acute icteric hepatitis without abdominal pain or fever. Average alanine aminotransferase levels were 39 times the normal rate. There was no sign of liver failure. All patients had anti-hepatitis C virus-positive serology and two had positive hepatitis C virus-RNA. Although no specific treatment was administered, buprenorphine doses were reduced whenever possible. Cytolysis and jaundice resolved rapidly in all cases, although treatment was continued at the same doses in four cases and the dosage was reduced by 50% in three other cases. CONCLUSIONS: Although buprenorphinehepatitis is uncommon and has spontaneously good evolution, we suggest better monitoring of hepatic profiles in patients whose mitochondrial function is already impaired by viral infections or other toxic factors.
Authors: Jeanette M Tetrault; Janet P Tate; E Jennifer Edelman; Adam J Gordon; Vincent Lo Re; Joseph K Lim; David Rimland; Joseph Goulet; Stephen Crystal; Julie R Gaither; Cynthia L Gibert; Maria C Rodriguez-Barradas; Lynn E Fiellin; Kendall Bryant; Amy C Justice; David A Fiellin Journal: J Subst Abuse Treat Date: 2016-06-06
Authors: Kenneth Blum; Thomas J H Chen; John Bailey; Abdalla Bowirrat; John Femino; Amanda L C Chen; Thomas Simpatico; Siobhan Morse; John Giordano; Uma Damle; Mallory Kerner; Eric R Braverman; Frank Fornari; B William Downs; Cynthia Rector; Debmayla Barh; Marlene Oscar-Berman Journal: Mol Neurobiol Date: 2011-09-24 Impact factor: 5.590
Authors: Michael P Bogenschutz; Patrick J Abbott; Robert Kushner; J Scott Tonigan; George E Woody Journal: J Addict Med Date: 2010-12 Impact factor: 3.702
Authors: David A Fiellin; Linda Weiss; Michael Botsko; James E Egan; Frederick L Altice; Lauri B Bazerman; Amina Chaudhry; Chinazo O Cunningham; Marc N Gourevitch; Paula J Lum; Lynn E Sullivan; Richard S Schottenfeld; Patrick G O'Connor Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Gregory M Lucas; Geetha Beauchamp; Apinun Aramrattana; Yiming Shao; Wei Liu; Liping Fu; J Brooks Jackson; David D Celentano; Paul Richardson; David Metzger Journal: Int J Drug Policy Date: 2011-08-17
Authors: Andrew J Saxon; Walter Ling; Maureen Hillhouse; Christie Thomas; Albert Hasson; Alfonso Ang; Geetha Doraimani; Gudaye Tasissa; Yuliya Lokhnygina; Jeff Leimberger; R Douglas Bruce; John McCarthy; Katharina Wiest; Paul McLaughlin; Richard Bilangi; Allan Cohen; George Woody; Petra Jacobs Journal: Drug Alcohol Depend Date: 2012-08-22 Impact factor: 4.492
Authors: Laura F McNicholas; Amber M Holbrook; Kevin E O'Grady; Hendrée E Jones; Mara G Coyle; Peter R Martin; Sarah H Heil; Susan M Stine; Karol Kaltenbach Journal: Addiction Date: 2012-11 Impact factor: 6.526